Drug intelligence / Profile preview

ONC-392 + docetaxel

Development stage: Unknown
Lead developer: OncoC4 and BioNTech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

**ONC-392 + docetaxel** is a combination currently being evaluated in phase 3 clinical trials for advanced non-small cell lung cancer (NSCLC) that is resistant to PD-1/PD-L1 inhibitor therapy. ONC-392 is a next-generation humanized anti–CTLA-4 IgG1 monoclonal antibody designed to selectively reduce regulatory T cells (Tregs) in the tumor microenvironment while preserving CTLA-4 protein recycling, thus enhancing antitumor activity and reducing toxicity compared to prior CTLA-4 antibodies. Docetaxel is a taxane-class cytotoxic chemotherapy agent that stabilizes microtubules, inhibiting cell division. The combination aims to synergistically enhance anti-tumor immune activity and cytotoxic effects in solid tumors, primarily NSCLC.

Other names: ONC-392 + docetaxel

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ONC-392 + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONC-392 + docetaxel.

Explore the full profile